Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cancer Antigen-specific T Cells in Lung Cancer
NCT03356808Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of 4SCAR-T (Shenzhen Geno-Immune Medical Institute) in lung cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
4SCAR-T (Shenzhen Geno-Immune Medical Institute)
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT03356808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356808.